Metanephric kidney development requires an inductive interaction between the ureteric bud and progenitor mesenchyme, where the early expression of two genes, Wilms' tumour 1 (WT1) and paired box 2 (Pax2), establishes critical but unknown developmental pathways. Indeed, transgenic mice with deregulated overexpression of Pax2 exhibit structural kidney defects and impaired renal function, as do mice harboring targeted disruptions and/or spontaneous mutations of either the Pax2 or WT1 genes. WT1 and Pax2 are thought to regulate each other's expression during renal development. To better define the relationship between WT1 and Pax2, we generated mouse embryos containing heterozygous mutations in both genes. WT1
Introduction
The mammalian kidney develops from reciprocal inductive interactions between the ureteric bud and the nephrogenic mesenchyme. Reiterative cycles of growth, branching and induction of the ureteric bud by the mesenchyme are accompanied by mesenchymal condensation and epithelialization to form the full complement of nephrons. Among the earliest genes to be expressed during nephrogenesis, with roles at both early and late stages in kidney development, are the Wilms' tumour 1 (WT1) tumour suppressor (Little et al., 1999) and the Paired box 2 (Pax2) (Eccles, 1998) genes.
WT1 is implicated in the etiology of childhood nephroblastoma (Wilms' tumour, WT). The WT1 gene encodes a zinc-finger transcription factor inactivated in B10-15% of sporadic WTs and in the germ line of children with a genetic predisposition to WTs (Little et al., 1999) . Through a number of mechanisms, which include alternative translation initiation, RNA editing and alternative splicing, the gene encodes 24 different isoforms (Lee and Haber, 2001) . Alternative splicing between the third and last WT1 zinc-fingers inserts or omits three amino acids (KTS), generating isoforms implicated in transcriptional regulation (ÀKTS) or RNA metabolism ( þ KTS) (Little et al., 1999) . WT1 has been shown to regulate the expression of several target genes, including those encoding growth factors, growth factor receptors, transcription factors, extracellular/secreted proteins and cell cycle control proteins (Lee and Haber, 2001) . It is also known to have several binding partners, many of which are also transcription factors and have been shown to alter the transcriptional regulatory properties of WT1 (Lee and Haber, 2001) .
Analysis of WT1 germline mutations in humans (Pelletier et al., 1991; Barbaux et al., 1997) , and targeted disruption of WT1 in the mouse (Kreidberg et al., 1993) support a role for WT1 in the control of genitourinary development (Little et al., 1999) . Analysis of WT1 gene mutations in mice with different genetic backgrounds suggests the presence of one or more modifier genes (Herzer et al., 1999; Kreidberg et al., 1999) . Mouse strains generated in which either of the WT1 ( þ /ÀKTS) isoforms have been removed underscore the importance of both isoforms in urogenital system development (Hammes et al., 2001) .
Pax2 is also implicated in the control of urogenital differentiation, as well as in the control of midbrainhindbrain, spinal cord, eye and ear development (Dahl et al., 1997) . Like other Pax proteins, Pax2 has been implicated in the maintenance of the transformed phenotype (Dressler and Douglass, 1992; Gnarra and Dressler, 1995; Muratovska et al., 2003) . Humans carrying a defective Pax2 allele exhibit renal hypoplasia, vesicoureteric reflux and optic nerve colobomas, a disease known as renal-coloboma syndrome (RCS) (Sanyanusin et al., 1995) . A mutant mouse strain (Pax2 1Neu ) has been described harboring a G397 insertion, which is identical to the Pax2 G619 insertion in humans (Favor et al., 1996; Porteous et al., 2000) . Heterozygous mutant mice exhibit kidney and eye defects, including renal hypoplasia and optic nerve coloboma. The renal defects show variable expressivity, with 1-6% of Pax2 1Neu/ þ mice reported to have only one kidney, and others observed to have frequently small and/or occasionally, cystic kidneys (Favor et al., 1996; Porteous et al., 2000) . Embryos homozygous for the Pax2 1Neu mutation fail to develop kidneys and die immediately after birth, due to the absence of kidneys. Homozygous deletion of the Pax2 gene results in embryos lacking kidneys, ureters and genital tracts (Torres et al., 1995) .
Although WT1 and Pax2 have been shown to play a critical role in the normal and abnormal development, the particular pathway(s) in which they function remains undefined. In transient transfection assays, Pax2 has been shown to activate the WT1 promoter (Dehbi et al., 1996; McConnell et al., 1997) . In parallel experiments, WT1 was shown to be a repressor of the Pax2 (Ryan et al., 1995) and WT1 promoters (Rupprecht et al., 1994) . This reciprocal control of gene expression between WT1 and Pax2 is consistent with the temporal and spatial pattern of WT1 and Pax2 gene expression during kidney development. As a means of further defining the potential interplay between WT1 and Pax2 during kidney development, we have analysed mouse embryos harboring heterozygous mutations of both WT1 and Pax2. Our results implicate WT1 and Pax2 as joint components in a common regulatory pathway essential for proper renal development.
Results

Viability and growth of mutant embryos
þ /À and C57BL/6 Pax2 1Neu/ þ mice were crossed in timed matings, and the number of offspring obtained for each of the genotypes was tabulated. Inheritance of the Pax2 1Neu/ þ allele and of both the Pax2
þ /À alleles together showed a deviation from the expected normal Mendelian inheritance (Table 1) . Although heterozygous WT1 þ /À offspring were obtained at a frequency similar to that of the wild-type embryos, we obtained 23% fewer Pax2 1Neu/ þ offspring and 49% fewer WT1 þ /À /Pax2 1Neu/ þ progeny than expected (Table 1) . These results indicate that prenatal lethality is associated with inheritance of the Pax2 1Neu mutation, as well as with inheritance of both WT1 and Pax2 1Neu mutations together. There was no significant difference in body weight observed among single and double heterozygous mutant embryos compared to wild-type embryos at E19 (data not shown).
1Neu/ þ mice were able to survive after birth.
Embryonic kidneys were removed from E19 embryos and weighed to compare their overall mass ( Figure 1a ). Double heterozygous mutant kidneys were significantly smaller than those of wild-type animals. Interestingly, the reduction was asymmetrical (48% smaller for the left kidney, 58% smaller for the right). As previously Figure 1 Weight and morphology of kidneys from mutant fetuses obtained from WT1 þ /À and Pax2 1Neu/ þ crosses differ substantially from those of wild-type littermates. (a) Weights (mean7s.e.) of individual left (gray bars) and right (black bars) kidneys from E19 fetuses were standardized to their respective embryo weight. The sample sizes for each genotype were: wild type: n-23 (L and R);
and n ¼ 15 (R). An asterisk above the bar indicates that a two-tailed Student's t-test yielded a P-value o0.01 for that weight compared to the wild-type weight. (b) Representative photomicrographs at E16 showing that kidneys from Pax2 1Neu/ þ and WT1 þ /À /Pax2 1Neu/ þ but not WT1 þ /À embryos are smaller with a reduced renal medulla, and fewer collecting ducts. At lower magnification (top panels), the reduction in size of the renal medulla (M), including calyces (Cx) and limited development of the renal pelvis (P) was obvious. At higher magnification (bottom four panels), reduction in the number of collecting ducts (CD) could be seen, and also attenuation of the nephrogenic zones (NZ) in the WT1 þ /À /Pax2 1Neu/ þ and Pax2 1Neu/ þ kidneys compared to wild-type kidneys. Glomeruli (G) in the WT1 þ /À /Pax2 1Neu/ þ kidneys appeared immature, but otherwise similar to Pax2 1Neu/ þ and wild-type kidneys. a, (scale bar: 10 mm) and b, (scale bar: 5 mm)
WT1 is a modifier of the Pax2 mutant phenotype MT Discenza et al reported (Favor et al., 1996; Porteous et al., 2000) , the kidneys from Pax2 1Neu/ þ mutants were also smaller (byB20%) than wild-type kidneys; there was no significant difference in size between WT1 þ /À and wildtype kidneys. These results suggest that kidneys derived from WT1
1Neu/ þ embryos are substantially less developed than those from wild-type, WT1
þ /À and Pax2 1Neu/ þ embryos. In the present study, the frequency of renal agenesis among WT1
1Neu/ þ embryos was 20% (3/15) and for Pax2 1Neu/ þ embryos was 6%, which is comparable to that previously reported for Pax2 1Neu/ þ embryos (Favor et al., 1996) . To identify the nature of the developmental abnormalities in the small double mutant kidneys, a preliminary investigation was carried out on E13, E16 and E19 kidneys from WT1
and wild-type embryos. At E13, mesonephroi and early metanephroi were visible, but no major difference was noted between wild-type and mutant embryos (data not shown). In contrast, kidneys from E16 and E19 (data not shown) WT1
þ /À /Pax2 1Neu/ þ and Pax2 1Neu/ þ embryos exhibited a morphologic phenotype consistent with the gross lesions described above (Figure 1b) . The characteristic WT1 þ /À /Pax2 1Neu/ þ phenotype was distinctly more severe than that of Pax2 1Neu/ þ mutants, and displayed variable expressivity. In contrast, kidneys of WT1 þ /À embryos had histological structures resembling wild-type littermates (Figure 1b) .
The most characteristic feature observed in H&E stained WT1
1Neu/ þ kidneys was the reduction in size of the renal medulla, including the size and number of renal calyces (Figure 1b ). There was a reduction in the volume of the collecting duct, and significantly fewer glomeruli in double mutants than in Pax2 1Neu/ þ kidneys, which in turn was less than in wild-type kidneys (Table 2) . These results were suggestive of less ureteric bud branching in the double mutants compared with Pax2 1Neu/ þ , WT1 þ /À and wild-type mice. As previously reported, Pax2 1Neu/ þ kidneys contained fewer differentiating nephrons, including fewer mesenchymal condensates, comma-shaped bodies, S-shaped bodies and glomeruli than wild-type littermates (Porteous et al., 2000) . Morphologically, the nephrogenic zones of WT1
1Neu/ þ kidneys were similar in appearance to Pax2 1Neu/ þ kidneys, except for the presence of a looser mesenchyme adjacent to ureteric bud structures, in contrast to the tight caps of condensed mesenchyme adjacent to ureteric bud structures in the kidneys of the other genotypes (Figure 1b) . The volume of the glomeruli of WT1 þ /À /Pax2 1Neu/ þ kidneys was similar to that of the WT1
1Neu/ þ and wild-type kidneys (Table 2) .
Immunohistochemical staining for WT1 and Pax2
We wished to further characterize the developmental abnormalities in the WT1
1Neu/ þ kidneys. The expression patterns of WT1 and Pax2 are themselves markers for kidney development, therefore we characterized the expression of WT1 and Pax2 proteins in kidneys of WT1
1Neu/ þ embryos at E16 (data not shown) and E19 ( Figure 2a , b) using immunohistochemistry. During differentiation of the nephron, the distributions of WT1 and Pax2 overlap, with both genes being coexpressed in the condensing mesenchyme and comma-shaped bodies (Ryan et al., 1995) . The expression of Pax2 protein declines in mesenchymally derived renal structures as renal differentiation proceeds, with strong Pax2 expression becoming restricted to the collecting ducts. In Figure 2b Analysis of WT1 and Pax2 mRNA levels in WT1
1Neu/ þ mice WT1 and Pax2 are postulated to influence significantly each other's expression during renal development in a temporal and spatial fashion (reviewed in Schedl and Hastie, 2000) . We performed quantitative real-time RT-PCR to compare WT1 and Pax2 mRNA levels in E19 kidneys from wild-type, WT1 Volume of an individual glomerulus plus Bowman's space *Denotes a significant difference (Po0.05) relative to the wild-type kidney measurement using a two-tailed Student's t-test embryos, WT1 mRNA levels were upregulated by B35% (Table 3) . Analysis of Pax2 mRNA levels revealed a significant 20-40% increase in expression in all mutant kidneys ( Table 3 ), suggesting that there may be some compensatory Pax2 transcription in Pax2 and WT1 mutant mice.
Apoptosis in WT1
þ /À /Pax2 1Neu/ þ kidneys A putative mechanism to account for attenuation of the renal medulla is apoptosis. The developing metanephric kidney contains extensive apoptosis, and we previously identified high levels of collecting duct apoptosis in E16 Pax2 1Neu/ þ kidneys compared with wild-type kidneys (Porteous et al., 2000) . To determine whether apoptosis is responsible for the hypoplastic phenotype in WT1
1Neu/ þ kidneys, we analysed the number of cells undergoing apoptosis in E16 fetal kidneys of wildtype and mutant fetuses. In Pax2 1Neu/ þ and WT1
1Neu/ þ fetal kidneys, the level of apoptosis over the whole kidney was elevated compared to wild-type kidneys (Table 4) . However, there was no significant difference between the levels of apoptosis in WT1
1Neu/ þ kidneys compared with Pax2 1Neu/ þ kidneys ( Table 4 ), suggesting that elevated apoptosis only partially accounts for the double mutant phenotype.
Interaction between WT1 and Pax2
We tested the potential for WT1 and Pax2 to interact both in vitro and in vivo. An in vitro pull-down assay was performed using 35 S-methionine-labeled Pax2a or Pax2b proteins with GST fused to either: (i) full-length WT1 (GST-WT1 (1-446)), (ii) the N-terminal domain of WT1 (GST-WT1 (1-242)) or (iii) the four WT1 zinc-fingers (GST-WT1 (297-446)) (Figure 3a) . In this setting, Pax2 did not associate with GST (Figure 3b , compare lanes 7 and 2 with lanes 6 and 1, respectively). In the presence of GST-WT1 (1-466), both Pax2a and Pax2b were associated with the glutathione-sepharose pellet (Figure 3b, lanes 3 and 8) , suggesting that Pax2 can (Figure 4 ). These results demonstrate that WT1 and Pax2 are capable of interacting in vivo.
To illustrate that the endogenous WT1 and Pax2 proteins interact, a total protein extract from E15 mouse kidneys was used in an immunoprecipitation/Western blot assay ( Figure 5 ). The protein extract was immunoprecipitated with anti-Pax2 antibody as well as nonimmune rabbit serum (NRS). The immunoprecipitates were then blotted with anti-WT1 antibody to detect the presence of WT1 in the immunoprecipitates. No protein was detected in the NRS immunoprecipitate ( Figure 5 ), indicating that WT1 does not interact nonspecifically with the antibody or the protein A-Sepharose. The anti-WT1 antibody specifically detected two proteins that coprecipitated with the anti-Pax2 immunoprecipitate ( Figure 5 ). The lower protein band, at around 50 kDa, represents the WT1 protein isoform synthesized through the use of the major initiator AUG. The larger protein band, at around 55 kDa, represents the larger WT1 protein isoform, WT1*, synthesized through translation initiation at a CUG codon 204 bases upstream of and in frame with the initiator AUG (Bruening and Pelletier, 1996) . These data suggest that the native WT1 and Pax2 proteins are able to interact physically and supports the data suggesting that WT1 and Pax2 interact in vivo.
Discussion
One of the first events to occur during nephrogenesis is the activation of WT1 and Pax2 expression following induction in the condensing metanephric mesenchyme. embryos are more severe than those observed in either WT1 þ /À or Pax2 1Neu/ þ embryos. A putative mechanism to account for the more severe phenotype of the double mutant kidneys is apoptosis. We previously identified high levels of collecting duct apoptosis in E16 Pax2 1Neu/ þ kidneys compared with wild-type kidneys (Porteous et al., 2000) . In this study, we analysed the number of cells undergoing apoptosis in E16 fetal kidneys of wildtype and mutant embryos and found that in Pax2
1Neu/ þ kidneys the level of apoptosis over the whole kidney was elevated compared to wildtype kidneys (Table 4) . However, there was no significant difference between the levels of apoptosis in double mutant WT1
1Neu/ þ kidneys compared with Pax2 1Neu/ þ kidneys ( Table 4 ), suggesting that elevated apoptosis appears not to account for the more severe phenotype of the double mutant kidneys.
Expressivity of kidney defects is reported to vary among Pax2 heterozygous mutant mice (Favor et al., 1996) . Our present findings support this conclusion as well as extend it to animals of the WT1 þ /À /Pax2 1Neu/ þ genotype. Genetic background has also been reported to affect the expressivity of the Pax2 mutant phenotype in different strains of mice (Torres et al., 1995) . In this regard, our results demonstrate that the genotype at the WT1 locus is at least one modifier of the Pax2 mutant phenotype, as the phenotype of the WT1 þ /À /Pax2 1Neu/ þ embryos is much more severe, but otherwise very similar to the Pax2 mutant phenotype. The exact stage at which the embryonic loss of Pax2 1Neu/ þ and WT1 þ /À /Pax2 1Neu/ þ embryos occurs at has not been defined in the present study. The presence of resorbed embryos, however, at the time of dissection (E14-E18), suggests that embryonic loss occurs at a stage postimplantation. We have yet to characterize the cause of prenatal lethality in the Pax2 1Neu/ þ and WT1
1Neu/ þ embryos. A reasonable hypothesis is that death results from an uncharacterized defect affecting another organ system since impaired renal development does not typically affect prenatal survival. We have examined multiple organs -chiefly of the cardiovascular, endocrine and nervous systems -of Pax2 1Neu/ þ and WT1 þ /À /Pax2 1Neu/ þ embryos for developmental defects; except for the kidneys, we noted no morphologic abnormalities. Given the extent of frank renal anomalies, it seems reasonable that the WT1
1Neu/ þ genotype will be associated with some degree of renal insufficiency, which, depending on the extent, might lead to postnatal lethality.
Immunohistochemical analysis of WT1 and Pax2 expression indicated that the spatial distribution of both proteins was similar among the four genotypes analysed, 1Neu/ þ or WT1 þ /À kidneys did not exhibit an expanded or persistent Pax2 expression pattern, hypoplastic kidneys with an identically expanded mesenchymal Pax2 expression pattern were observed in WT1-null mutant kidneys partially complemented with a WT1 YAC transgene (Moore et al., 1999) . These results suggest that at sufficiently low dosage, or in WT1
1Neu/ þ mutants, WT1 fails to restrict Pax2 expression. It could be envisaged that abnormal Pax2 expression patterns alter cell lineage specification in the condensing mesenchyme (for example, stromal cell determination), which subsequently affects development of the renal medulla.
WT1 was expressed at reduced levels in WT1 þ /À and WT1
1Neu/ þ kidneys relative to kidneys from wild-type fetuses, consistent with loss of one functional allele in these fetuses (Table 3 ). The severe phenotype observed in the WT1
1Neu/ þ kidneys does not therefore appear to result from further deregulation of WT1 gene expression due to haploinsufficiency for Pax2 (Table 3) . Surprisingly, WT1 levels were slightly elevated in Pax2 1Neu/ þ kidneys. This might suggest that Pax2 (directly or indirectly) may act to repress WT1 expression, although we cannot rule out nonspecific effects on WT1 mRNA turnover in these mutants.
Renal Pax2 expression was increased by approximately 20-40% in kidneys of all three mutant fetuses relative to kidneys of wild-type fetuses, suggesting that compensatory upregulation of Pax2 transcription may occur in Pax2 and WT1 heterozygous mutants. Unlike the WT1 mutant allele, in which the WT1 promoter and first exon have been targeted, the Pax2 1Neu mutation is a frameshift mutation in which the mutant allele is transcribed and is available for amplification by RT-PCR. Hence, in Pax2 1Neu/ þ and WT1 1Neu/ þ kidneys is not likely due to further deregulation of Pax2 gene expression due to haploinsufficiency for WT1.
Other determinants of kidney lineage differentiation analysed by real-time PCR in wild-type and mutant kidneys included glial cell line-derived neurotrophic factor (Gdnf), expressed in the condensing mesenchyme, brain factor 2 (Bf2), expressed in the stromal cells, bone morphogenic protein 7 (Bmp7), expressed in the ureteric bud and mesenchyme, Podl, expressed in the podocytes and Wnt4, expressed in the mesenchyme. The products of these genes have been shown to direct the earliest stages of kidney development (reviewed in Schedl and Hastie, 2000) . Thus, any changes in renal expression of these genes in the WT1
1Neu/ þ kidneys compared to the WT1 þ /À , Pax2 1Neu/ þ and wild-type kidneys would serve to underscore which renal-specifying pathway(s) had been disrupted during development of the double mutant kidneys. However, the expression levels obtained for these genes in the present study were not well correlated with the divergent kidney phenotypes among the different genotypes, and therefore provided inconclusive results regarding the interactions of WT1 and Pax2 with these other renal morphogens (unpublished results).
The major phenotype in the WT1
kidneys was marked attenuation of the renal medulla, although WT1 is never expressed in ureteric bud-derived cells. Interestingly, failure of ureteric bud outgrowth was observed in WT1 null mouse embryos, suggesting that signals in the mesenchyme are required for inducing ureteric bud outgrowth (Kreidberg et al., 1993; Moore et al., 1999) . We postulate that the comparatively severe renal malformations in WT1
fetuses results from abnormal function of a regulatory pathway incorporating both WT1 and Pax2 in the condensing mesenchyme, leading to either abnormal mesenchymederived cell lineage specification, and/or abnormal interactions between the mesenchyme and the ureteric bud. Our data show that WT1 and Pax2 proteins interact in vivo and that the amino-terminal 242 amino acids of WT1 are sufficient for this interaction (Figures  3-5) . The developmental pathway interrupted by the WT1 þ /À /Pax2 1Neu/ þ mutation does not appear to result from a grossly altered level of either transcription factor. On the other hand, our data suggest it is likely to be the result of a decreased dosage of both WT1 and Pax2 proteins together. Demonstrable dosage sensitivity of either WT1 or Pax2 in heterozygous mutant animals typifies the essential role of these proteins in kidney development (Torres et al., 1995; Moore et al., 1999) , although Pax2 appears to be more dosage-sensitive than WT1. In this regard, WT1 þ /À mice have relatively normal kidneys.
The most likely scenario to explain the phenotype of the WT1
1Neu/ þ fetuses is that Pax2 and WT1 proteins are involved in a complex required during the early mesenchyme-epithelial transition, where this complex is sensitive to a threshold level of both WT1 and Pax2 in order to form. We do not presently have data to indicate which developmental pathway has been disrupted. WT1(ÀKTS) isoforms bind DNA, and preferentially associate with the transcriptional apparatus, yet WT1 ( þ KTS) isoforms preferentially associate with splice factors (reviewed in Little et al., 1999; Schedl and Hastie, 2000) . Therefore, WT1/Pax2 complexes could be involved in the processing, trafficking or metabolism of cellular mRNA. Alternatively, WT1/ Pax2 complexes could be involved in transcription elongation or chromatin conformation. Analysis of the DNA-binding ability of the WT1/Pax2 complex will reveal whether the complex is able to interact with previously identified WT1 and/or Pax2 binding sites.
WT1 has been shown to regulate the expression of genes such as the epidermal growth factor receptor (EGFR) (Englert et al., 1995) . Pax2 (Dressler et al., 1990) , insulin-like growth factor-II (IGF-II) (Drummond et al., 1992) , IGF-I receptor (IGF-IR) (Werner et al., 1995a, b) , podocalyxin (Palmer et al., 2001) , vitamin D receptor (VDR) (Lee and Pelletier, 2001) and Wnt-4 (Sim et al., 2002) . Pax2 can regulate the expression of the WT1 gene (Dehbi et al., 1996; McConnell et al., 1997) . If the WT1/ Pax2 complex is able to interact with WT1 and/or Pax2 binding sites, this complex may be involved in differentially regulating the expression of WT1 and/or Pax2 downstream target genes. Alternatively, if the WT1/ Pax2 complex has DNA-binding properties different than WT1 and/or Pax2, a new set of target genes may be regulated.
Other protein partners have been identified for both WT1 and Pax2 that affect the transcriptional regulatory properties of the two proteins. WT1 has been shown to interact with p53, p73, p63, Par-4, CIAO-1, hUBC 9, HSP 70, WTAP, CBP/P300, SF-1, WT1 and BMZF2 (Lee and Haber, 2001; Lee et al., 2002) . A Pax2 interacting protein has been identified and named PTIP for Pax transactivation-domain interacting protein (Lechner et al., 2000) . Studies with the Pax2/5/ 8 family of proteins have suggested that Pax2 may also interact with corepressor proteins of the Groucho family (Eberhard et al., 2000) as well as with members of the ETS family of transcription factors (Wheat et al., 1999) . These WT1 and Pax2 protein partners could also interact with WT1/Pax2 complexes, forming ternary protein complexes capable of transcriptional regulation or chromatin modification. Taken together, our data suggest that WT1 and Pax2 are critical components in a common regulatory pathway that specifies cell differentiation in the developing kidney.
Materials and methods
Mouse breeding and genotyping
WT1
þ /À C57BL/6 (strain name: B6.129S4-WT1
tm/Jae
) and wild-type C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Pax2 1Neu C57BL/6 mice (Favor et al., 1996) were obtained from Dr Jack Favor (Neuherberg, Germany). WT1 and Pax2 heterozygous mutant strains were maintained by mating heterozygous mutant males with wild-type females. The morning on which a copulation plug was found was designated embryonic day 0.5 (E0.5).
For genotyping, genomic DNA was prepared from mouse tail slices or embryonic tissue. Genotyping for the WT1 gene was carried out by PCR amplification using the following three primers simultaneously: mWT1-S: 5 0 CTAATCTCCTAAAG-TGACCC3 0 , mWT1-AS: 5 0 TGCCCCCAGCTTCCCAAA3 0 and mPGK1-AS: 5 0 AGACGTGCTACTTCCATTTGT3 0 . The wild-type WT1 allele was amplified by primers mWT1-S and mWT1-AS to produce a 510 bp band. The mutant WT1 allele was amplified by primers mWT1-S and mPGK1-AS to produce a 290 bp band. Genotyping for the Pax2 gene was carried out by PCR amplification (Primer 1: 5 0 GCCCAG-GATTTTGCTGACACAGCC3 0 ; Primer 2: 5 0 GTGTGAA-CCAGCTCGGGGGTG3 0 ). Amplification of the mutant Pax2 allele with these two primers introduces an XcmI restriction enzyme site in the product, whereas amplification of the wild-type Pax2 allele does not. An aliquot of each reaction was digested with XcmI (New England Biolabs (NEB)) and analysed on a 15% polyacrylamide gel. Wild-type samples were identified by the presence of a 166 bp undigested product, whereas Pax2 1Neu/ þ samples were identified by the presence of the 166 bp undigested product and a 151 bp digested product. All genotyping reactions were performed in duplicate.
Immunohistochemical procedures
Pax2 and WT1 stainings were carried out as previously described Porteous et al., 2000) , with modifications. Microwave antigen retrieval using 0.01 M citrate buffer (pH 7.0 and pH 2.0, respectively) was performed twice for 5 min each (Evers and Uylings, 1994) . The Pax2 and WT1 primary antibodies were rabbit anti-murine Pax2 (Zymed) (1 : 50) or rabbit anti-human WT1 (Santa Cruz) (1 : 100). The secondary antibody was biotinylated goat anti-rabbit IgG, which was incubated on the slides at RT for 30 min followed by avidin biotinylated horseradish peroxidase (HRP) H complex for 30 min according to the manufacturer's instructions (Vector Laboratories). Peroxidase activity was developed for 2 min at RT using diaminobenzidene tetrachloride (DAB; Zymed) as the chromogen, with hematoxylin as the counterstain.
Stereological analysis of mutant and wild-type kidneys
Whole E16 fetal mice, six for each genotype (wild-type, WT1
, were fixed, embedded in paraffin, and sagitally serial sectioned through the whole mouse, at a thickness of 4 mm. Six pairs of sections were collected in a systematic uniform manner starting from a randomly chosen first section. Hematoxylin-stained sections were photographed, and the structural features identified in the photograph. Stereological analysis was carried out according to Gunderson et al. (1998) . The Cavalieri method was used to estimate the kidney volume, and the physical dissector/Cavalieri method was used to estimate glomerular number. Collecting duct volume was determined using an indirect estimation of component volume by determining the volume fraction, and the mean glomerular volume was determined using the point-sample intercept method.
Quantitation of WT1 and Pax2 mRNA levels in kidneys
Relative expression levels were assessed in 30 or 300 ng of total RNA by real-time, one-step RT-PCR using the Roche LightCycler Instrument and the Roche LightCycler -RNA Master SYBR Green 1 kit. Known concentrations of in vitro transcribed Pax2a were used as RT-PCR templates to establish a standard curve for quantitation. b2-microglobin (b2 M) expression was measured in individual kidneys and used as an internal control to standardize gene expression measurements. The following primers were used: (i) for WT1, mWT1-F: 5 0 GTGCCCAGTACAGAATACAC3 0 ; mWT1-R: 5 0 CACTGGTTTCAGATGCTGAC3 0 ; for Pax2, mPax2-F: 5 0 GTTCCCAGTGTCTCATCCAT3 0 ; mPax2-R: 5 0 GGCGT-TGGGTGGAAAGG3 0 ; and for b2 M, mb2M-F: 5 0 TGCA-GAGTTAAGCATGACAGTATGG3 0 ; and mb2M-R: 5 0 TG-ATGCTTGATCACATGTCTCG3 0 .
Detection of apoptosis (TUNEL assay)
The terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling (TUNEL) assay was performed on paraffinembedded tissue sections as described (Porteous et al., 2000) , except that the detection was by fluorescence according to the manufacturer's instructions (Roche). Briefly, paraffin sections were dewaxed, rehydrated and partially digested with 20 mg/ml proteinase K in 10 mM Tris-HCl (pH 7.5) at room temperature for 10 min. The sections were then incubated for 60 min at 371C with TUNEL reaction mixture containing TdT and FITC-dUTP. Fluorescent digital images were collected, areas measured using NIH image (version 1.62), TUNEL-positive signals counted and the data analysed statistically using the Student t-test (No30).
In vitro transcription/translations and GST Pull-down assays
In vitro transcription of pKSII/Pax2a and pKSII/Pax2b constructs were performed using T7 RNA polymerase (NEB) on templates that had been linearized with EcoRI (NEB).
In vitro translations were performed in the presence of [
35 S]methionine in rabbit reticulocyte lysate, essentially as described by the manufacturer (Promega). Glutathione S-transferase (GST) and GST/WT1 fusion proteins were purified according to the manufacturer's recommendations (Pharmacia). GST pull-down experiments were performed essentially as previously described (Kim et al., 2000) .
Immunoprecipitation-Western blot assays
Cos7 cells were cotransfected by calcium phosphate precipitation with 5 mg of CMV/WT1( þ /À)/HA together with 5 mg of pcDNA3, CMV/Pax2a, or CMV/Pax2b DNA (Dehbi et al., 1996) . After 48 h, cells were lysed in lysis buffer (50 mM HEPES (pH 7.9), 400 mM NaCl, 0.1% NP40, 10% glycerol, 0.2 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 1 mM Na 3 VO 4 , 5 mM NaF, 100 000 IU aprotinin) for 30 min on ice. After preclearing cell lysates with protein A-Sepharose, extracts were incubated with anti-Pax2 antibodies (Zymed) overnight, and immune complexes were collected with Protein ASepharose beads at 41C for 1 h. The beads were washed six times with lysis buffer, and the proteins were eluted with 1 Â SDS loading buffer. Proteins were separated by electrophoresis through a 10% polyacrylamide/SDS gel and transferred to an Immobilon-P membrane (Millipore). After blocking with 5% skim milk in phosphate-buffered saline/ Tween-20 (PBST) (9.1 mM dibasic sodium phosphate, 1.7 mM monobasic sodium phosphate, 150 mM NaCl, 0.05% Tween-20, pH 7.4), the membrane was incubated for 1 h with anti-HA antibody (1 : 1000) (HA.11, BAbCO). The membrane was washed in PBST, and antibody binding was visualized with peroxidase-conjugated goat anti-mouse secondary antibody (1 : 5000) (Amersham) utilizing ECL reagents (Amersham).
Native coimmunoprecipitations of WT1 and Pax2
For the analysis of the interaction between endogenous WT1 and Pax2, embryonic mouse kidneys (E15) were lysed using a syringe with an 18G11/2 needle in lysis buffer (20 mM HEPES-KOH (pH 7.9), 400 mM KCl, 0.1% NP40, 0.2 mM EDTA, 0.2% EGTA, 10% glycerol, 5 mM NaF, 1 mM DTT, 1 mM Na 3 VO 4 , 1 mg/ml of aprotinin, 1 mg/ml of leupeptin, 1 mg/ml of prefaBloc, and 1 mg/ml of pepstatin A) and incubated for 30 min on ice. Extracts were incubated with either NRS or anti-Pax-2 antibodies (Zymed) overnight, and immune complexes were collected with protein A-Sepharose beads at 41C for 1 h. The beads were washed six times with lysis buffer, and the proteins were eluted with 1 Â SDS loading buffer. Immunoprecipitates were separated by SDS-PAGE and detected by Western blotting using anti-WT1 antibody (F-6, Santa Cruz Biotechnology).
